NLM Logo

Clinical Trials, Phase I as Topic MeSH Descriptor Data 2023


MeSH Heading
Clinical Trials, Phase I as Topic
Tree Number(s)
E05.318.372.250.250.200
N05.715.360.330.250.250.200
N06.850.520.450.250.250.200
Unique ID
D017321
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D017321
Annotation
for general design, methodology, economics, etc. of phase I clinical trials; a different heading CLINICAL TRIAL, PHASE I is used for reports of a specific phase I clinical trial
Scope Note
Works about studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the U.S. and in other countries.
Entry Term(s)
Clinical Trials, Phase 1
Clinical Trials, Phase I
Drug Evaluation, FDA Phase 1
Drug Evaluation, FDA Phase I
Drug Evaluation, FDA Phase I as Topic
Evaluation Studies, FDA Phase 1
Evaluation Studies, FDA Phase I
Human Microdosing Trial
Human Microdosing Trials
Microdosing Trials, Human
Phase 1 Clinical Trial
Phase 1 Clinical Trials
Phase I Clinical Trial
Phase I Clinical Trials
Previous Indexing
Clinical Trials (1980-1992)
Drug Evaluation (1980-1992)
See Also
Nontherapeutic Human Experimentation
Public MeSH Note
2008; see CLINICAL TRIALS, PHASE I 1993-2007; for DRUG EVALUATION, FDA PHASE I see DRUG EVALUATION 1980-1992; for EVALUATION STUDIES, FDA PHASE I see DRUG EVALUATION 1982-1992
History Note
2008(1993)
Date Established
1993/01/01
Date of Entry
1992/05/13
Revision Date
2020/05/27
Clinical Trials, Phase I as Topic Preferred
Evaluation Studies, FDA Phase I Narrower
Microdosing Trials, Human Narrower
Drug Evaluation, FDA Phase I as Topic Narrower
page delivered in 0.153s